The New Normal: Dr. Ihor Sawczuk, Dr. Bruce Farber talk vaccine trials, promising Moderna news
As cases of COVID-19 continue to rise across the country, we got another good piece of news this week, with Moderna seeing 94% effectiveness in its vaccine thus far.
We're joined by Dr. Bruce Farber, Dr. Ihor Sawczuk, a Long Island COVID-19 survivor and more in this week's New Normal special.
Here are some highlights from the special.
Two straight Mondays with big vaccine news - here's Dr. Farber's reaction:
Messenger RNA has been a point of conversation in these trials. Farber explains why it's a great development:
One of the big developments from Moderna's trials is the difference in temperature it can be stored at. Here's what that means:
Why be part of the COVID-19 vaccine trials? Hackensack Meridian Health's Dr. Ihor Sawczuk tells us about his thought process:
Sawczuk also talked about the importance of having sizable, diverse demographics in the trials: